Comparison between Non-alcoholic fatty liver disease Fibrosis Score in Diabetic and Non-diabetic Egyptian patients

Document Type : Original Article

Authors

1 Endemic Medicine Department, Faculty of Medicine Beni-Suef University, Egypt

2 Clinical and chemical pathology department, faculty of medicine, benisuef university

Abstract

The aim of the present study was to compare NAFLD fibrosis score in diabetic and non-diabetic Egyptian patients to clarify the effect of diabetes on the development of fibrosis and NASH in NAFLD patients. This was a comparative anterospective observational study. 50 Egyptian patients with characteristic sonographic features and laboratory findings suggesting Non-alcoholic fatty liver disease were included. The patients were divided into two groups; Diabetic group and Non-diabetic group according to American diabetic association criteria 2015 comparing the NAFLD fibrosis score in both groups which uses six commonly measured parameters. Mean ±SD of NAFLD fibrosis score was -7.5± 0.97 in the non-diabetic group and 1.58± 1.9 in the diabetic group showing significant difference among the studied groups, as the lowest scores were in non-diabetic group, and the highest scores were in the diabetic group. This showing prevalence of advanced hepatic disease in Diabetic group more than non-diabetic group. The lower serum albumin and platelet count in combination with a higher AST to ALT ratio seen with the DM patients reflect the higher prevalence of advanced fibrosis as they are recognized markers of hepatic synthetic function, portal hypertension and surrogates of advanced fibrosis respectively. We concluded that; more aggressive NAFLD as suggested by the higher NAFLD fibrosis score was seen in DM patients compared to non-DM patients.

Keywords

Main Subjects

References

  1. Younossi ZM, Koenig AB, Abdelatif D, et al. (2016). Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64(1):73–84.
  2. Younossi Z, Anstee QM, Marietti M, et al. (2018). Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterology Hepatology, 15(1):11–20.
  3. Xiao G, Zhu S, Xiao X, et al. (2017). Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology, 66(5):1486–501.
  4. Chalasani N, Younossi Z, Lavine JE, et al. (2012). The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 55:2005-2023.
  5. Stinton LM, Loomba R. (2014). Recommendations for liver biopsy evaluation in non-alcoholic fatty liver disease. Minerva Gastroenterology Dietology, 60:5–13.
  6. Angulo P, Hui JM, Marchesini G, et al. (2007). The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 45: 846-54.
  7. EASL, Marchesini G, Day CP, et al. (2016). EASLEASD-EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease. J Hepatol., 64:1388–1402.
  8. Bae JC, Rhee EJ, Lee WY, et al. (2011). Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: A 4-year retrospective longitudinal study. Diabetes Care, 34(3):727–729.
  9. Goh GB-B, Pagadala MR, Dasarathy J, et al. (2015). Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clinical, 2015(3): 141-5.
  10. Simeone JC, Bae JP, Hoogwerf BJ, et al. (2017). Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol., 9: 679-88.
  11. Singh A, Le P, Peerzada MM, et al. (2018). The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 2 diabetic patients. Journal of Clinical Gastroenterology, 52: 268-72.
  12. Forlani G, Giorda C, Manti R, et al. (2016). The burden of NAFLD and its characteristics in a nationwide population with type 2 diabetes. Journal of Diabetes Research, 1: 1-6.
  13. Nakahara T, Hyogo H, Yoneda M, et al. (2014). Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. Journal of Gastroenterology, 49: 1477-84.
  14. Lee J-H, Kim D, Kim HJ, et al. (2010). Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Digestive and Liver Disease, 2010(42): 503-8.
  15. McPherson S, Stewart SF, Henderson E, et al. (2010). Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut, 59: 1265-9.
  16. Wai CT, Greenson JK, Fontana RJ, et al. (2003). A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology, 38: 518-26.
  17. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. (2015). Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology, 149: 367-378.
  18. Lombardi R, Airaghi L, Targher G, et al. (2020). NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes. Journal of Diabetes and its Complications, 34: 107-111.
  19. Younossi ZM, Gramlich T, Matteoni CA, et al. (2004). Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clinical Gastroenterology and Hepatology, 2: 262-65.
  20. Adams LA, Harmsen S, Sauver JLS, et al. (2010). Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. The American Journal of Gastroenterology, 105: 1567-71.
  21. Ekstedt M, Franzén LE, Mathiesen UL, et al. (2006). Long‐term follow‐up of patients with NAFLD and elevated liver enzymes. Hepatology, 44: 865-73.
  22. Paradis V, Perlemuter G, Bonvoust F, et al. (2001). High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology, 34: 738-44.

Files

Share

How to cite

Statistics